Paul Shields

All filings by Paul Shields on record concern Unigene Laboratories Inc. Between 21 March 2006 and 21 December 2011, the trades on record add up to 13 filings.

The open-market side counts 1 purchase for €802 alongside 5 sales for €197k. Sales outweigh purchases by €196k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants and 5 option exercises. Since January 2011: 1 purchase and no sales on the market.

Most recently, on 22 December 2011, the filings show an open-market purchase worth €802 in Unigene Laboratories Inc. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.